- Home
- MOLN vs SPKL Comparison
MOLN vs SPKL Comparison
Compare MOLN & SPKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- SPKL
- Stock Information
- Founded
- MOLN 2004
- SPKL 2021
- Country
- MOLN Switzerland
- SPKL United States
- Employees
- MOLN N/A
- SPKL N/A
- Industry
- MOLN
- SPKL
- Sector
- MOLN
- SPKL
- Exchange
- MOLN Nasdaq
- SPKL Nasdaq
- Market Cap
- MOLN 195.4M
- SPKL 174.6M
- IPO Year
- MOLN 2021
- SPKL 2023
- Fundamental
- Price
- MOLN $5.33
- SPKL $10.69
- Analyst Decision
- MOLN
- SPKL
- Analyst Count
- MOLN 0
- SPKL 0
- Target Price
- MOLN N/A
- SPKL N/A
- AVG Volume (30 Days)
- MOLN 6.0K
- SPKL 25.1K
- Earning Date
- MOLN 03-13-2025
- SPKL 01-01-0001
- Dividend Yield
- MOLN N/A
- SPKL N/A
- EPS Growth
- MOLN N/A
- SPKL N/A
- EPS
- MOLN N/A
- SPKL 0.19
- Revenue
- MOLN $7,105,397.00
- SPKL N/A
- Revenue This Year
- MOLN N/A
- SPKL N/A
- Revenue Next Year
- MOLN $29.41
- SPKL N/A
- P/E Ratio
- MOLN N/A
- SPKL $57.67
- Revenue Growth
- MOLN N/A
- SPKL N/A
- 52 Week Low
- MOLN $3.32
- SPKL $10.19
- 52 Week High
- MOLN $12.70
- SPKL $11.95
- Technical
- Relative Strength Index (RSI)
- MOLN 49.14
- SPKL 63.48
- Support Level
- MOLN $5.25
- SPKL $10.63
- Resistance Level
- MOLN $5.33
- SPKL $10.69
- Average True Range (ATR)
- MOLN 0.20
- SPKL 0.02
- MACD
- MOLN 0.02
- SPKL 0.00
- Stochastic Oscillator
- MOLN 44.23
- SPKL 100.00
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.